Patents by Inventor Evangelos Tziampazis

Evangelos Tziampazis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9029144
    Abstract: The present invention relates generally to methods for the isolation and propagation of cells. For example, embodiments of the present invention relate to isolation and propagation methods for the manufacture of a large number of cells for use, for example, in biotherapeutic devices, such as devices for renal replacement therapy for the treatment of acute renal failure (ARF), acute tubular necrosis (ATN), multi-organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end-stage renal disease (ESRD).
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: May 12, 2015
    Assignees: Innovative Bio Therapies, Inc., CytoPherx, Inc.
    Inventors: Mark Szczypka, Evangelos Tziampazis, Angela J. Westover
  • Publication number: 20100136687
    Abstract: The present invention relates generally to methods for the isolation and propagation of cells. For example, embodiments of the present invention relate to isolation and propagation methods for the manufacture of a large number of cells for use, for example, in biotherapeutic devices, such as devices for renal replacement therapy for the treatment of acute renal failure (ARF), acute tubular necrosis (ATN), multi-organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end-stage renal disease (ESRD).
    Type: Application
    Filed: June 16, 2009
    Publication date: June 3, 2010
    Inventors: Angela J. Westover, Mark Szczypka, Evangelos Tziampazis
  • Patent number: 7332330
    Abstract: A device and a method of maintaining vascularization near an implant, especially a bioartificial hemofilter. By associating cells that excrete angiogenic factors with such an implant, vascularization to the tissue surrounding the implant can be maintained. In a bioartificial hemofilter, this facilitates filtrate transport to a collection fiber for drainage from the body. The cells can be genetically engineered, for example using an adenovirus vector encoding for vascular endothelial growth factor. Myoblasts and myotubes may be used in one embodiment of the present invention.
    Type: Grant
    Filed: September 11, 2001
    Date of Patent: February 19, 2008
    Assignee: RenaMed Biologics, Inc.
    Inventors: H. David Humes, William H. Fissell, Deborah A. Buffington, Evangelos Tziampazis
  • Publication number: 20060177478
    Abstract: Disclosed is an implantable, intravascular device for treating a medical disorder associated with the presence of a particular molecule in the systemic circulation of a mammal. When implanted, the device removes or reduces the concentration of the molecule in the blood stream thereby conditioning the blood. The device includes an anchor component immobilizable to an inner wall of an intact blood vessel and a cartridge component that is retained in place within the blood vessel by the immobilized anchor. The cartridge contains a converting agent, for example, viable cells or enzyme preparations, that catabolize or convert the molecule of interest into one or more other molecules that are not associated with the disorder. The invention also provides a minimally or non-invasive method for introducing into and, optionally, removing from the blood vessel the device of the invention.
    Type: Application
    Filed: March 24, 2006
    Publication date: August 10, 2006
    Inventors: H. Humes, Evangelos Tziampazis, Richard Andrews
  • Publication number: 20030050622
    Abstract: A device and a method of maintaining vascularization near an implant, especially a bioartificial hemofilter. By associating cells that excrete angiogenic factors with such an implant, vascularization to the tissue surrounding the implant can be maintained. In a bioartificial hemofilter, this facilitates filtrate transport to a collection fiber for drainage from the body. The cells can be genetically engineered, for example using an adenovirus vector encoding for vascular endothelial growth factor. Myoblasts and myotubes may be used in one embodiment of the present invention.
    Type: Application
    Filed: September 11, 2001
    Publication date: March 13, 2003
    Applicant: The University of Michigan
    Inventors: H. David Humes, William H. Fissell, Deborah A. Buffington, Evangelos Tziampazis
  • Publication number: 20020090389
    Abstract: Disclosed is an implantable, intravascular device for treating a medical disorder associated with the presence of a particular molecule in the systemic circulation of a mammal. When implanted, the device removes or reduces the concentration of the molecule in the blood stream thereby conditioning the blood. The device includes an anchor component immobilizable to an inner wall of an intact blood vessel and a cartridge component that is retained in place within the blood vessel by the immobilized anchor. The cartridge contains a converting agent, for example, viable cells or enzyme preparations, that catabolize or convert the molecule of interest into one or more other molecules that are not associated with the disorder. The invention also provides a minimally or non-invasive method for introducing into and, optionally, removing from the blood vessel the device of the invention.
    Type: Application
    Filed: November 30, 2001
    Publication date: July 11, 2002
    Inventors: H. David Humes, Evangelos Tziampazis, Richard A. Andrews
  • Publication number: 20020090388
    Abstract: Disclosed is an implantable drug delivery device for delivering a pre-selected drug directly into the systemic circulation of an animal. The device comprises an anchor immobilizable to an inner wall of an intact blood vessel. The device also comprises a drug containing reservoir that is retained in place within the blood vessel by the immobilized anchor. The reservoir may include, for example, a drug containing osmotic pump or a drug permeable capsule having disposed therein drug containing particles, which release the drug directly into blood passing the reservoir. The invention also provides a minimally invasive method for introducing into a blood vessel and, optionally, removing from the blood vessel the drug delivery device of the invention.
    Type: Application
    Filed: November 30, 2001
    Publication date: July 11, 2002
    Inventors: H. David Humes, Evangelos Tziampazis